Stomach cancer is the second most common cancer worldwide ([Parkin *et al*, 1999](#bib18){ref-type="other"}). In Japan, this cancer is the leading cause of cancer death among women and the second among men ([Statistics and Information Department, Minister\'s secretariat, Ministry of Health and Welfare Japan, 2000](#bib21){ref-type="other"}). It has recently been reported that green tea consumption is inversely associated with the risk of stomach cancer; in other words, it has a protective effect. Green tea polyphenols have various anticarcinogenic effects, such as strong antioxidant activity, and inhibition of nitrosation and cell proliferation.

Although case--control studies ([Kono *et al*, 1988](#bib13){ref-type="other"}; [Yu and Hsieh, 1991](#bib29){ref-type="other"}; [Yu *et al*, 1995](#bib28){ref-type="other"}; [Ji *et al*, 1996](#bib12){ref-type="other"}; [Inoue *et al*, 1998](#bib11){ref-type="other"}; [Setiawan *et al*, 2001](#bib20){ref-type="other"}) have found a reduced risk of stomach cancer in association with green tea consumption, prospective studies ([Galanis *et al*, 1998](#bib8){ref-type="other"}; [Nakachi *et al*, 2000](#bib16){ref-type="other"}; [Nagao *et al*, 2001](#bib15){ref-type="other"}; [Tsubono *et al*, 2001](#bib25){ref-type="other"}) have not. A recent prospective study found that green tea had a protective effect against stomach cancer. Urinary tea polyphenols have been associated with protection from the risk of stomach cancer, while controlling *Helicobacter pylori* infection. Past studies did not consider the presence or absence of a history of infection with *H. pylori*, a strong risk factor for stomach cancer ([Asaka *et al*, 1997](#bib1){ref-type="other"}). Assuming that green tea consumption is related to *H. pylori* infection, when a subject has a history of infection with *H. pylori* and consumes a large quantity of green tea, the protective effect, if any, would be masked. The present nested case--control study aimed to examine the association between green tea consumption and the risk of stomach cancer, while controlling *H. pylori* infection and other potential confounders, using data from the Japan Collaborative Cohort (JACC) Study, a Japan-wide population-based prospective study. This is the first study to analyse the effects of green tea consumption while controlling *H. pylori* infection.

MATERIAL AND METHODS
====================

JACC Study
----------

This study was part of the Japan Collaborative Cohort Study for Evaluation of Cancer Risk sponsored by the Ministry of Education, Science, Sports and Culture of Japan (the JACC Study), a nation-wide multicentre collaborative study to prospectively evaluate various risk or protective factors for cancer mortality and incidence. Details of the study design were reported previously. Briefly, the cohort included 110 792 men and women (46 465 and 64 327, respectively), aged 40--79 years at recruitment, who were enrolled from 1988 to 1990. Enrollment was based on the participants of a general health checkup periodically provided by the 45 municipalities involved. The informed consent procedures were approved by the Ethics Committee of Medical Care and Research, University of Occupational and Environmental Health, Kitakyushu, and the Ethical Board of the Nagoya University School of Medicine, Japan.

At the time of recruitment, baseline characteristics were gathered by a self-administered questionnaire, which covered the medical history and included items such as drinking and smoking, level of education, and family history of several medical conditions including cancer. About one-third of the cohort members (*n*=39 293) also donated a residual serum sample (about 2 ml) to be used for the general health checkup. This sample was partitioned into 0.3--0.5 ml aliquots and stored at −80°C, until laboratory analyses were performed. The *H. pylori* antibody level was measured in the serum using HM-CAPTM (Enteric Products, Westbury, NY, USA) with an antigen from Japanese (J-HM-CAP). The cutoff value was determined at 2.3, which was recommended in the manufacturer\'s instructions.

Follow-up and identification of stomach cancer cases, and selection of control subjects
---------------------------------------------------------------------------------------

The vital status of each participant was checked annually by each regional research centre, with permission from the Ministry of Public Management, Home Affairs, Post and Telecommunications to review their population register sheets. The incidence of cancer was ascertained in 24 study areas (*n*=65 184) and coded according to the tenth revision of the International Classification of Disease and the second edition of the International Classification of Diseases for Oncology. These data were collected at the central office of the Research Committee.

We first restricted the subjects to those who lived in the study areas where cancer incidence was ascertained. We then excluded 857 participants with a self-reported history of cancer. From the remaining 64 327 subjects, diagnosis of stomach cancer at 12 or more months after cohort recruitment was documented in 804 subjects until the end of 1997. Serum had been obtained from 218 cases of the initial 804 cases. However, seven cases without sufficient serum for the laboratory analyses and one case without an eligible control subject were excluded. Thus, the study reported here included 210 cases in total. There were no differences between those selected for the case--control study nested within the cohort and those who were not selected in terms of the variables included in the multivariate model. The lag time between blood sampling and stomach cancer diagnosis varied between 12 and 113 months (median, 50 months). Each of these subjects was matched with two control subjects with respect to sex, age at recruitment (as near as possible), and study area, who had also provided an adequate baseline blood sample, and who were alive and free of confirmed cancer by the end of 1997. Owing to a lack of eligible subjects, a few sets (*n*=10) contained only one control, and thus there was a total of 410 controls.

Since questions on the daily consumption of green tea were not included in the questionnaire in seven areas (four rural areas and three urban/rural areas), we excluded these data (49 cases and 88 controls). Of the 161 cases and 322 controls remaining, eight cases (5.0%) and 38 controls (11.8%) had green tea consumption data missing from the questionnaire; so these too were excluded. Owing to a lack of eligible subjects, 16 sets were further excluded. The remaining 151 cases and 265 controls were included in the present analysis.

Data processing
---------------

Cox proportional hazard regression analysis was used. The relative risk (RR) and its 95% confidence interval (CI) were calculated based on the regression coefficient and its standard error ([Cox, 1972](#bib7){ref-type="other"}), for an indicator term corresponding to the level of an independent variable. For multivariate analysis, several factors were listed as potential confounders according to epidemiological studies ([Boeing, 1991](#bib5){ref-type="other"}; [Hoshiyama and Sasaba, 1992](#bib9){ref-type="other"}; [World Cancer Research Fund, 1997](#bib26){ref-type="other"}; [Hoshiyama *et al*, 2002](#bib10){ref-type="other"}; [Yatsuya *et al*, 2002](#bib27){ref-type="other"}). Trends of association were assessed by the regression model assigning scores (0--4) to the levels of the independent variables. Statistical significance (two-sided) was based on the ratio of the regression coefficient and its standard error. Statistical analysis (PHREG procedure) was performed using the Statistical Analysis System ([SAS Institute, 1983](#bib19){ref-type="other"}).

RESULTS
=======

[Table 1](#tbl1){ref-type="table"} Table 1Characteristics of cases and controls **CaseControlNo151265**Age (years)61.761.5*Green tea (cups per day)* \<11831 1 or 21923 3 or 44173 5--950105 ⩾102333*H. pyroli infection (%)*88.777.7History of peptic ulcer (%)19.718.2Family history of stomach cancer (%)^a^20.516.2⩽9 years of schooling (%)^b^37.132.0*Smoking (%)*   Current32.228.7 Past18.518.0*Daily dietary consumption (%)* Rice (⩾4 bowls day^−1^)36.531.8 Miso soup (⩾1 cup day^−1^)83.777.9 Preference for salty foods (yes)33.829.6 Green-yellow vegetables (⩾1 day^−1^)46.742.3 White vegetables (⩾1 day^−1^)38.640.5 Fruits (⩾3 week^−1^)44.439.3[^2][^3] compares the characteristics of the cases and the controls. The consumption of green tea varied substantially. The proportion with a history of *H. pylori* infection was higher for the cases than for the controls. The proportion with a family history of stomach cancer was also higher for the cases than for the controls. The proportion of current smokers was also higher for the cases than for the controls. The cases consumed rice, miso soup, green--yellow vegetables, and fruit more frequently than the controls.

[Table 2](#tbl2){ref-type="table"} Table 2Relative risk of stomach cancer according to green tea consumption **Green tea consumption (cups day^−1^)** **\<11 or 23 or 45--9⩾10*P* for trend**Case/controls18/3119/2341/7350/10523/33 Age/sex-adjusted RR1.01.2 (0.5--2.9)0.9 (0.4--1.9)0.7 (0.3--1.5)1.0 (0.4--2.4)0.515Age/sex- and *H. pylori*-adjusted RR1.01.1 (0.4--2.9)0.9 (0.4--1.9)0.7 (0.3--1.5)1.1 (0.4--2.5)0.628Multivariate RR^a^1.01.3 (0.6--2.8)1.0 (0.5--1.9)0.8 (0.4--1.6)1.2 (0.6--2.5)0.899[^4] shows the RR and its CI for stomach cancer according to green tea consumption. The age/sex-adjusted RRs associated with drinking one or two, three or four, five to nine, and 10 or more cups of green tea per day, relative to those of drinking less than one cup per day, were 1.2 (95% CI: 0.5--2.9), 0.9 (95% CI: 0.4--1.9), 0.7 (95% CI: 0.3--1.5), and 1.0 (95% CI: 0.4--2.4), respectively. Multivariate RRs were similar to age/sex-adjusted and age/sex- and *H. pylori* infection-adjusted RRs.

[Table 3](#tbl3){ref-type="table"} Table 3Relative risk of *H. pylori* infection positive according to green tea consumption among controls **Green tea (cups day^−1^)** **\<11 or 23 or 45--9⩾10P for trend**Age--sex-adjusted RR of *H. pylori* infection positive1.01.0 (0.2--3.8)1.0 (0.3--2.8)1.1 (0.4--3.1)0.7 (0.2--2.5)0.901 shows the age/sex-adjusted RRs of *H. pylori* infection positivity according to green tea consumption. *H. pylori* infection did not differ with the consumption of green tea.

DISCUSSION
==========

This nested case--control study is the first study to investigate any association between green tea consumption and the risk of stomach cancer while controlling *H. pylori* infection. Among the possible limitations of the present study was incomplete data. About 10% of subjects were excluded from the analysis because they had not provided information concerning their daily consumption of green tea. We could not fully evaluate the effects of the exclusion of these data. Nevertheless, there was no difference between the percentages of smokers in the whole data (53.1% of men and 2.9% of women) and those in the included data (51.9% and 3.7%, respectively), as examined by the Cochran--Mantel--Haenszel *χ*^2^ test (*P*=1.000 and 0.843, respectively). The missing information therefore seemed to occur randomly.

The second possible problem with the present study was in the questionnaire. The original words of the question on green tea were: Do you drink Japanese tea (green tea)? There are various kinds of Japanese tea, although for Japanese people green tea is the one that most often comes to mind. About 89% of the total production of Japanese tea in 1999 was ordinary green tea ([The Ministry of Agriculture, Forestry, and Fisheries, 1999](#bib24){ref-type="other"}). We believe that a slight misclassification could have derived from the idiosyncrasy of our questionnaire pertaining to Japanese tea (green tea).

Green tea is widely consumed in Japan and other Asian countries. If drinking green tea protects against stomach cancer, it would be an inexpensive and convenient method of primary prevention. Tsubono *et al* reported that there was no association between green tea consumption and the risk of stomach cancer, consistent with the finding of this prospective study. Little other evidence is available from prospective studies ([Galanis *et al*, 1998](#bib8){ref-type="other"}; [Tsubono *et al*, 2001](#bib25){ref-type="other"}). Past studies did not consider the influence of *H. pylori* infection. Subjects with chronic gastritis caused by *H. pylori* infection might have limited their consumption of green tea. If so, the prevalence of infection would have been lower in the subjects with higher intakes of green tea. If not, the prevalence of infection would have been higher among the subjects with higher intakes of green tea. This condition would have masked an inverse association between the risk of stomach cancer and green tea consumption. We examined the association of *H. pylori* infection and green tea consumption, and found that *H. pylori* infection did not differ with the consumption of green tea (see [Table 3](#tbl3){ref-type="table"}).

Our findings are in general agreement with those of four prospective studies which found no inverse association between green tea consumption and the risk of stomach cancer ([Galanis *et al*, 1998](#bib8){ref-type="other"}; [Nakachi *et al*, 2000](#bib16){ref-type="other"}; [Nagao *et al*, 2001](#bib15){ref-type="other"}; [Tsubono *et al*, 2001](#bib25){ref-type="other"}). The number of cases of stomach cancer was relatively large in three studies. Recently, another prospective study was conducted in Shanghai, China. Urinary EGC positivity showed a statistically significant inverse association with stomach cancer (OR=0.52, 95% CI=0.28--0.97) after adjustment for *H. pylori* seropositivity, smoking, alcohol drinking, and the level of serum carotenes ([Sun *et al*, 2002](#bib23){ref-type="other"}). Cumulative excretion of EGC increased with increasing green tea consumption in human subjects ([Yang *et al*, 1998](#bib30){ref-type="other"}). It might be important to evaluate biomarkers of tea polyphenol exposure.

In summary, we found no inverse association between the consumption of green tea and the risk of stomach cancer in Japan in a nested case--control study.
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[^1]: See the appendix for the investigators (name and affiliation) involved in the JACC Study

[^2]: We defined a positive family history of stomach cancer as when the subject had a least one first-degree relative (parents or siblings) with a history of stomach cancer.

[^3]: Information on educational level was measured as the age of formal schooling completed and was classified into two categories: ⩽15 years old (corresponds to ⩽9 years of schooling) and ⩾16 years old (corresponds to ⩾10 years of schooling).

[^4]: Adjusted for age (four classes), smoking status (never, past, current), sex, *H. pylori* infection, history of peptic ulcer, family history of stomach cancer, educational level (two levels), consumption of rice, miso soup, green--yellow vegetables, white vegetables, fruits, and preference for salty foods (two categories). Values in parantheses are 95% confidence intervals. RR=relative risk.
